Introduction While bevacizumab inhibits tumor angiogenesis, it can temporarily ‘normalize’ tumor blood vessels, improve tumor blood flow and oxygen supply, thereby enhancing the effects of radiotherapy and chemotherapy. Therefore, bevacizumab as neoadjuvant therapy or radiosensitizer on the prognosis of patients with locally advanced cervical cancer (III-IVA stage) deserves further study.

Methods This study retrospectively analyzed and compared the prognosis of patients with locally advanced (III-IVA stage) cervical cancer who were diagnosed and treated in our hospital from 2019 to 2022. The primary endpoint was progression-free survival, and the secondary endpoint was overall survival.

Results There were 57 people in the bevacizumab combined with radiochemotherapy group, and 152 people in the radiochemotherapy group during the same period. There was no significant difference in OS between the two groups. At 12 months, 18 months, 24 months, and 36 PFS, the bevacizumab combined with chemoradiotherapy group was significantly higher than that of the radiochemotherapy group, and the comparison between the two groups was statistically significant.

Conclusion/Implications The recurrence rate within 3 years of patients with locally advanced (III-IVA stage) cervical cancer treated with bevacizumab combined with radiochemotherapy was significantly lower than that of patients with radiochemotherapy. The primary treatment with bevacizumab combined with radiochemotherapy can significantly improve the prognosis of locally advanced (III-IVA stage) cervical cancer patients.